Author:
Puertas Borja,Rey-Búa Beatriz,Eiros Rocío,Martín-Arribas Alberto,Montero-Mateos Enrique,Hernández-Sánchez Alberto,Gómez-Úbeda Sandra,Alejo-Alonso Elena,Martín-López Ana A.,Antúnez Patricia,Villacorta-Argüelles Eduardo,Gallego-Delgado María,Puig Noemi,Mateos María-Victoria,González-Calle Verónica
Abstract
There is no recommendation on what salvage therapy is optimal in the solid organ recipient with AL amyloidosis, such as a heart transplant. With this case, we illustrate how treatment with daratumumab may be effective and safe in a patient with AL amyloidosis with renal involvement at the relapse after heart transplantation and autologous stem cell transplantation.